Skip to content
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Nephrology

Building Your Care Team and Preparing for Visits

At a Glance

People with brachydactyly-arterial hypertension syndrome benefit from a coordinated team led by a clinician experienced in monogenic hypertension. Bring the PDE3A report, X-rays, blood-pressure records, and medication history, and discuss cascade testing with a genetic counselor.

Because Brachydactyly-Arterial Hypertension Syndrome (HTNB) is an ultra-rare condition, you are unlikely to find a single “HTNB clinic.” Instead, you must assemble a coordinated team of specialists who understand the unique intersection of genetics, skeletal development, and vascular health [1][2].

Building this team is about more than just finding doctors; it is about creating a network that can manage a lifelong, multi-system condition and protect your family members who may also be at risk [1][3].

Essential Members of Your Care Team

A successful care team for HTNB typically includes specialists who can address both the genetic cause and the physical effects of the syndrome. A practical core team includes:

  • Hypertension Specialist (Nephrologist or Cardiologist): This is often the “anchor” of your team. You need a physician (pediatric or adult) who specializes in difficult-to-treat or monogenic hypertension—high blood pressure caused by a single gene [4][5].
  • Clinical Geneticist and Genetic Counselor: These specialists help interpret your PDE3A lab report, coordinate testing for family members, and discuss reproductive options [2][6].
  • Primary Care Clinician and Pharmacist: Essential for coordinating your overall health, routine care, and managing complex medication schedules.

Based on symptoms, family history, or local expertise, your team may also bring in a Cardiovascular Genetics Specialist or a Vascular Neurologist [7][1][8].

Preparing for Your First Consultation

When you meet with a specialist for the first time, you are often teaching them about your rare diagnosis as much as they are treating you. To make the most of these visits, arrive with a organized “dossier” of your health:

  1. The Genetic Gold Standard: Bring the original laboratory report for your PDE3A mutation. Ensure it includes the exact variant notation, its specific location, and the laboratory’s classification (e.g., “Pathogenic” or “Likely Pathogenic”) [9][8].
  2. Skeletal Records: Bring physical copies or digital files of hand and foot X-rays. Reports alone are helpful, but specialists often want to see the specific bone shortening and growth plate patterns themselves [10][2].
  3. Blood Pressure Logs: Provide a detailed history of your blood pressure readings, including any 24-hour ambulatory blood pressure monitoring (ABPM) reports [11][1].
  4. Medication History: List every blood pressure medication you have taken, the dosage, how long you took it, and whether it was effective or caused side effects [11][1].

Portable Emergency Card Template

Consider carrying a card that includes:

  • Confirmed Diagnosis (HTNB) and exact PDE3A pathogenic variant.
  • Your usual blood pressure target and current medicines.
  • Treating clinician’s name and contact information.
  • A note stating: “Patient has a rare monogenic hypertension syndrome requiring clinician-directed, individualized blood pressure management.”
    (Share this with emergency clinicians, but note that it does not replace their acute assessment.)

Family Screening: Cascade Testing

HTNB is an autosomal dominant condition, meaning it is often passed directly from a parent to a child [1][12]. Once a PDE3A mutation is identified in you (the proband, or first identified person in a family), “cascade testing” is recommended for your first-degree relatives—your parents, siblings, and children [13][14].

  • Why Test Relatives? Finding the gene mutation early allows family members to start protective blood pressure management before internal damage occurs [1][15].
  • The Process: Relatives should receive professional genetic counseling before testing to understand the implications of the results, including privacy and reproductive questions [6]. Testing is typically done through a simple blood or saliva sample that looks specifically for the known familial pathogenic variant [16][14].
  • Important Caveats: A “Variant of Uncertain Significance” (VUS) should not be used alone to label or reassure relatives. Relatives who test negative for the known familial pathogenic variant generally do not inherit that familial risk, but their own blood pressure still deserves ordinary clinical care. While testing is being arranged, relatives should have their blood pressure assessed clinically.

Evaluating a Specialist’s Expertise

Because you are managing an ultra-rare disease, it is reasonable to vet your doctors. A specialist who is a good fit for HTNB should be comfortable answering questions about:

  • Their experience with monogenic (single-gene) versus common hypertension [4].
  • How they integrate genetic results into a daily treatment plan [5].
  • Their willingness to collaborate with rare disease researchers or experts at other institutions [17][5].

If a doctor is unfamiliar with HTNB, their willingness to learn and coordinate with your geneticist is often more important than their initial knowledge of the syndrome [18].

Common questions in this guide

Which specialists should be involved in HTNB care?
Care usually includes a nephrologist or cardiologist experienced in difficult-to-treat or monogenic hypertension, along with a clinical geneticist, genetic counselor, primary care clinician, and pharmacist. Other specialists may be added based on symptoms, family history, and local expertise.
What should I bring to my first HTNB specialist appointment?
Bring the original PDE3A genetic report, including the exact variant and laboratory classification, as well as hand and foot X-rays. Blood pressure logs, ambulatory monitoring reports, and a complete list of blood pressure medicines, doses, effects, and side effects are also useful.
Should my relatives be tested for HTNB?
When a pathogenic PDE3A variant has been identified, first-degree relatives such as parents, siblings, and children should discuss targeted cascade testing with a genetic counselor. Testing usually uses a blood or saliva sample to look for the known familial variant, and relatives should have their blood pressure assessed while testing is arranged.
How should a variant of uncertain significance be handled in my family?
A variant of uncertain significance should not be used by itself to diagnose HTNB or reassure a relative that they are unaffected. Clinical blood pressure monitoring and guidance from a genetic counselor are important while the result is being evaluated.
How can I choose a doctor who understands HTNB?
Ask whether the clinician treats monogenic hypertension, knows how to use PDE3A results in daily care, and is willing to coordinate with genetics specialists or rare disease experts. A willingness to learn and collaborate can be as important as prior experience with HTNB.
What information belongs on an HTNB emergency card?
The card can list the confirmed diagnosis, exact pathogenic PDE3A variant, usual blood pressure target, current medicines, and treating clinician’s contact information. It should explain that individualized blood pressure management is needed, but it does not replace an emergency clinician’s assessment.

Get notified when new evidence is published on Brachydactyly-arterial hypertension syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (18)
  1. 1

    Hypertension and Brachydactyly Syndrome Associated With Vertebral Artery Malformation Caused by a PDE3A Missense Mutation.

    Fan P, Zhang D, Yang KQ, et al.

    American journal of hypertension 2020; (33(2)):190-197 doi:10.1093/ajh/hpz151.

    PMID: 31549136
  2. 2

    PDE3A gene screening improves diagnostics for patients with Bilginturan syndrome (hypertension and brachydactyly syndrome).

    Renkema KY, Westermann JM, Nievelstein RAJ, et al.

    Hypertension research : official journal of the Japanese Society of Hypertension 2018; (41(11)):981-988 doi:10.1038/s41440-018-0094-5.

    PMID: 30209282
  3. 3

    Strategies for improving the treatment and control of hypertension in Japan.

    Sakima A, Matayoshi T, Arima H

    Journal of human hypertension 2024; (38(6)):510-515 doi:10.1038/s41371-022-00708-7.

    PMID: 35660794
  4. 4

    Monogenic forms of low-renin hypertension: clinical and molecular insights.

    Khandelwal P, Deinum J

    Pediatric nephrology (Berlin, Germany) 2022; (37(7)):1495-1509 doi:10.1007/s00467-021-05246-x.

    PMID: 34414500
  5. 5

    Genetic screening for monogenic hypertension in hypertensive individuals in a clinical setting.

    Bao M, Li P, Li Q, et al.

    Journal of medical genetics 2020; (57(8)):571-580 doi:10.1136/jmedgenet-2019-106145.

    PMID: 32561571
  6. 6

    Cardiovascular genetics: the role of genetic testing in diagnosis and management of patients with hypertrophic cardiomyopathy.

    Ahluwalia M, Ho CY

    Heart (British Cardiac Society) 2021; (107(3)):183-189 doi:10.1136/heartjnl-2020-316798.

    PMID: 33172912
  7. 7

    PDE3A variant associated with hypertension and brachydactyly syndrome in a patient with ischemic stroke caused by spontaneous intracranial artery dissection: A review of the clinical and molecular genetic features.

    Lee CG, Kang K, Yoon RG, et al.

    European journal of medical genetics 2020; (63(4)):103781 doi:10.1016/j.ejmg.2019.103781.

    PMID: 31589936
  8. 8

    Mutant Phosphodiesterase 3A Protects From Hypertension-Induced Cardiac Damage.

    Ercu M, Mücke MB, Pallien T, et al.

    Circulation 2022; (146(23)):1758-1778 doi:10.1161/CIRCULATIONAHA.122.060210.

    PMID: 36259389
  9. 9

    Whole-exome sequencing identifies a de novo PDE3A variant causing autosomal dominant hypertension with brachydactyly type E syndrome: a case report.

    Li X, Li Z, Chen P, et al.

    BMC medical genetics 2020; (21(1)):144 doi:10.1186/s12881-020-01077-z.

    PMID: 32631253
  10. 10

    Hypertension With Brachydactyly Syndrome: A Case Report.

    Asim R, Reddy A, Grigorieva Olson O, et al.

    Cureus 2020; (12(5)):e8329 doi:10.7759/cureus.8329.

    PMID: 32617206
  11. 11

    When and how to use ambulatory blood pressure monitoring and home blood pressure monitoring for managing hypertension.

    Lee EM

    Clinical hypertension 2024; (30(1)):10 doi:10.1186/s40885-024-00265-w.

    PMID: 38556887
  12. 12

    PDE3A mutations cause autosomal dominant hypertension with brachydactyly.

    Maass PG, Aydin A, Luft FC, et al.

    Nature genetics 2015; (47(6)):647-53 doi:10.1038/ng.3302.

    PMID: 25961942
  13. 13

    Genetic testing for inherited arrhythmia syndromes and cardiomyopathies: results of the European Heart Rhythm Association survey.

    Zeljkovic I, Gauthey A, Manninger M, et al.

    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2024; (26(9)) doi:10.1093/europace/euae216.

    PMID: 39148456
  14. 14

    Role of Genetics in Diagnosis and Management of Hypertrophic Cardiomyopathy: A Glimpse into the Future.

    Abbas MT, Baba Ali N, Farina JM, et al.

    Biomedicines 2024; (12(3)) doi:10.3390/biomedicines12030682.

    PMID: 38540296
  15. 15

    A Novel Frameshift Mutation of SCNN1G Causing Liddle Syndrome with Normokalemia.

    Fan P, Zhao YM, Zhang D, et al.

    American journal of hypertension 2019; (32(8)):752-758 doi:10.1093/ajh/hpz053.

    PMID: 30977777
  16. 16

    Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

    Richards S, Aziz N, Bale S, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2015; (17(5)):405-24 doi:10.1038/gim.2015.30.

    PMID: 25741868
  17. 17

    Massively parallel sequencing and targeted exomes in familial kidney disease can diagnose underlying genetic disorders.

    Mallett AJ, McCarthy HJ, Ho G, et al.

    Kidney international 2017; (92(6)):1493-1506 doi:10.1016/j.kint.2017.06.013.

    PMID: 28844315
  18. 18

    Phenotypic and molecular reanalysis of a cohort of patients with monogenic diabetes reveals a case of partial lipodystrophy due to the A8344G mutation in the mitochondrial DNA.

    Franco PC, Patrocinio M, Costa-Riquetto AD, et al.

    Archives of endocrinology and metabolism 2024; (68()):e230084 doi:10.20945/2359-4292-2023-0084.

    PMID: 39420889

This page is for informational purposes only and does not replace medical advice. Your treating clinicians and genetic counselor should guide blood pressure management, genetic testing, and family screening.